RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
Grazie Aureliano 💙👇
Fate il test. Fatelo.
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
RT @baboskibe: ⏬⏬
⏬⏬
RT @AurelianoStingi: Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potreb…
🔴🔴🔴🔴👇👇👇👇👇👇🔴🔴🔴🔴🔴🔴
Una donna su 9 nel corso della sua vita svilupperà un tumore al seno. Lo sapete che esiste un test genetico che potrebbe evitare al 70% delle donne la chemioterapia? 1/n https://t.co/nZ0TXha2sq
RT @tsonipeled: @statsepi OncotypeDx in breast cancer. 21-gene assay https://t.co/WSx6rt4E9O
@statsepi OncotypeDx in breast cancer. 21-gene assay https://t.co/WSx6rt4E9O
@kim_builta @DrAttai The earliest studies on 21 gene recurrence score =Oncotype was published in 2004 but the landmark study (TailorX) was published 2018 https://t.co/1XmaMPxcGw #bcsm
RT @kazusanH: オンコタイプDXでRS11-25の人に対しては、ホルモン療法に化学療法を併用しても効果はホルモン療法単独と差がない =ケモの上乗せ効果はない ただし、50歳以下ではケモを併用した方が治療成績は良く、9年再発率は RS16-20の人では1.6% RS…
化学療法benefitについて このような研究結果があります ご参考になさって下さい
オンコタイプDXでRS11-25の人に対しては、ホルモン療法に化学療法を併用しても効果はホルモン療法単独と差がない =ケモの上乗せ効果はない ただし、50歳以下ではケモを併用した方が治療成績は良く、9年再発率は RS16-20の人では1.6% RS21-25の人では6.5% 下がる https://t.co/SXlUQMPvBM
@joebeattie @ddiamond @drkevinknopf @OncLive I would say that is where the desperation is justified. Here is one study that shows moving faster as in giving women chemo and targeted drugs with early breast cancer is overall not good for women: https://t.co
OncotypeDx is now recommended by NCCN guidelines based on TAILORx trial (https://t.co/Aof50F8TRm).The trial tested all surgical specimens with Onctotype and showed that women with intermediate RS (11-25) had comparable outcomes with endocrine therapy alone
@JonMarronMD @ASCO @BurrisSkip @LGG1 @tonsterps @DannyGrayson913 @CliffordHudis @drdonsdizon @myESMO @NarjustDumaMD Dr. @jsparano referred to TAILORx participants as women or pts in the @NEJM paper (https://t.co/2OMGqQpR2d) & as trial volunteers in his
RT @GlassmanDS: #TAILORx study shows chemotherapy can be spared in about 70% of women with ER +ve, HER2 -ve, node -ve #BreastCancer. Women…
RT @hiroirohiro33: 再発スコア~10:ホルモン療法 再発スコア26~:化学療法+ホルモン療法 再発スコア11~25: 基本的には化学療法を追加する意義なし。 但し、50歳以下で再発スコアが16~25の場合、化学療法を足すメリット有り。 https://t.co…
再発スコア~10:ホルモン療法 再発スコア26~:化学療法+ホルモン療法 再発スコア11~25: 基本的には化学療法を追加する意義なし。 但し、50歳以下で再発スコアが16~25の場合、化学療法を足すメリット有り。 https://t.co/x3urBTvpTY
@RogueRad @DanielJafari Is this general statement, or limited to radiology? OncotypeDx predicts 10-year breast cancer recurrence, and isn't useless: https://t.co/CzSrazEXbA
RT @NatRevClinOncol: The ASCO clinical practice guidelines relating to the use of biomarkers to guide decisions on adjuvant systemic therap…
RT @NatRevClinOncol: The ASCO clinical practice guidelines relating to the use of biomarkers to guide decisions on adjuvant systemic therap…
RT @NatRevClinOncol: The ASCO clinical practice guidelines relating to the use of biomarkers to guide decisions on adjuvant systemic therap…
RT @NatRevClinOncol: The ASCO clinical practice guidelines relating to the use of biomarkers to guide decisions on adjuvant systemic therap…
RT @NatRevClinOncol: The ASCO clinical practice guidelines relating to the use of biomarkers to guide decisions on adjuvant systemic therap…
RT @NatRevClinOncol: The ASCO clinical practice guidelines relating to the use of biomarkers to guide decisions on adjuvant systemic therap…
RT @NatRevClinOncol: The ASCO clinical practice guidelines relating to the use of biomarkers to guide decisions on adjuvant systemic therap…
The ASCO clinical practice guidelines relating to the use of biomarkers to guide decisions on adjuvant systemic therapy for women with early stage #breastcancer have been updated (https://t.co/vfQ8YENZxM) to integration of results from TAILORx (https://t
The TAILORx trial looked at women whose prognosis based off a gene panel was neither low nor high risk (but rather middle) to see whether chemotherapy was necessary. The results from this trial suggested the middle set of patients don’t need chemotherapy.
RT @gomezalvaro: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/t1MF3lGZVy
RT @gomezalvaro: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/t1MF3lGZVy
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/t1MF3lGZVy
RT @3ctnNews: The TAYLORx | MAC.12 study shows tremendous impact in changing the landscape of standard of care for women with breast cancer…
The TAYLORx | MAC.12 study shows tremendous impact in changing the landscape of standard of care for women with breast cancer. Congratulations again for your publication @CDNCancerTrials in @NEJM in 2018. Read the article: https://t.co/4FcsceGCht
@MaartenvSmeden @AndrewLBeam @EricTopol @drsxr @vcheplygina @dinga92 Afirma thyroid cancer test: https://t.co/CcV7pntfDV But authors are mixed. Also Oncotype Dx breast cancer recurrence test, independent authors: https://t.co/CzSrazEXbA Though some disp
This last week will be dedicated to articles published in 2018. To start off: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. This assay predicts the benefit of chemotherapy based on high and low risk scores. https://t.co/lgvp
Women with most common type of early stage BC likely don't need chemo after surgery. 5 yrs after treatment, rate of invasive disease-free survival: 93.1% for those who had chemo vs 92.8% for those who didn't (9 yrs 84.3% vs 83.3%) https://t.co/sbdeZ1FY9x &
Basado en este artículo: https://t.co/7U679YUPhi https://t.co/FLIPYgWwdR
@f2harrell @ProfHayward @ATorkamani @boback @venkmurthy @cecilejanssens @amitvkhera @skathire @matthewherper @B_resnick @NatureGenet Oncotype DX is prospectively validated https://t.co/CzSrazEXbA, included in major oncology guidelines, reimbursed, used wor
Necesidad del uso quimioterapia adyuvante según la expresion de 21 genes en el cáncer de mama. N Engl J Med. 2018. https://t.co/Bl5GJvx4eF. Amplia tus conocimientos en el tema acudiendo al simposio de cancer de mama, 13 y 14 septiembre, Madrid. https://t.c
RT @Hirokensamba: 今回の研究では、この遺伝子検査を利用した対象患者さんの約70%は抗がん剤を避けられることが判明。 https://t.co/x3urBTdOvo
今回の研究では、この遺伝子検査を利用した対象患者さんの約70%は抗がん剤を避けられることが判明。 https://t.co/x3urBTdOvo
(1/2): The inclusion of #chemotherapy treatment alongside #hormonetherapy for the majority of women with the most common form of #breastcancer isn't effective according to a clinical trial in @NEJM. https://t.co/kob6GMRSGR #precisionmedicine
Adjuvant #Chemotherapy Guided by a 21-Gene Expression Assay in #Breast #Cancer | NEJM https://t.co/lsu5tJ9CWF
RT @NEJMGroup: Top studies published in @NEJM this week during #ASCO18: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/20…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. Via @NEJM. https://t.co/gmG1pJM2oj
@EricTopol What are the inclusion/exclusion criteria for the list? TAILORx https://t.co/CzSrazEXbA is a prospective, rigorous validation of OncotypeDX #MachineLearning algorithm in a real-world setting. Used widely to guide breast cancer treatment
TAILORxの続報。OncotypeDxで中間リスク集団で、HT単独はChT+HTと比較して再発率で非劣勢と示された。 https://t.co/AyRuzpT1rY
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. https://t.co/tVhuAUUr47
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
Unnecessary Adjuvant Chemotherapy in Breast Cancer https://t.co/rQ4b15lb0s #TAILORx
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s Editorial:…
RT @kappel0208: 今月、米国臨床腫瘍学会での乳がん治療に関する最新報告。 リンパ節転移のない一般型の乳がん女性のうち、少なくとも70%は化学療法を不要とする結果が示されました。 さらに化学療法の必要性そのものに再検討を要する内容となっています。 https://t…
やはり…癌患者は医療業界の良いお客さんなのか? https://t.co/IOGP9pfI9C
RT @zakkohane: Utility of mid-range 21-Gene Expression Score in Breast #Cancer another argument for automated decision support in #oncolog…
TAILORx data are important but we have been using this in clinic and guidelines for 10+ years https://t.co/eZ6FW34Aft
Utility of mid-range 21-Gene Expression Score in Breast #Cancer another argument for automated decision support in #oncology https://t.co/jqXnMvzH7u
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s Editorial:…
I've learned in residency the value of reading editorials as they can put studies into context and even help me understand the study better! https://t.co/bCQXsEof3x
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s Editorial:…
Habrá que incluir este método despistase en nuestros centros, la evidencia lo aconseja. https://t.co/CFK3RI9XA6
RT @mnaesens: New milestone in clinical impact of #biomarker research - #Oncotype DX 21-gene #expression assay helps decisions about adjuva…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s Editorial:…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in #BreastCancer https://t.co/rQ4b15lb0s Editorial:…